Marshall Stanton - Feb 23, 2023 Form 4 Insider Report for ARTIVION, INC. (AORT)

Role
SVP, Clinical & MD Affair
Signature
/s/ Marshall Stanton
Stock symbol
AORT
Transactions as of
Feb 23, 2023
Transactions value $
-$30,236
Form type
4
Date filed
3/1/2023, 05:27 PM
Previous filing
Jan 27, 2023
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AORT Common Stock Award $0 +3.77K +9.32% $0.00 44.2K Feb 23, 2023 Direct F1
transaction AORT Common Stock Sale -$15.2K -1.18K -2.66% $12.94 43K Feb 27, 2023 Direct F2
transaction AORT Common Stock Award $0 +7.44K +17.29% $0.00 50.5K Feb 23, 2023 Direct F3
transaction AORT Common Stock Sale -$15K -1.16K -2.3% $12.94 49.3K Feb 27, 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents performance stock units granted on Feb 23, 2022. Hundred percent (100%) were issued on Feb 23, 2023.
F2 These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction.
F3 Represents performance stock units granted on Feb 23, 2022. Fifty percent (50%) were issued on Feb 23, 2023. The remaining shares earned in connection with the Feb 2022 grant will be eligible to vest and be issued as follows: 25% on 02/23/2024, and 25% on 02/23/2025, assuming continued employment on the relevant vesting date.